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ABSTRACT
Introduction: Excessive group 2 carbapenem use may result in decreased bacterial susceptibility. 
Objective: We evaluated the impact of a carbapenem stewardship program, restricting imipenem and 
meropenem use. Methods: Ertapenem was mandated for ESBL-producing Enterobacteriaceae infections 
in the absence of non-fermenting Gram-negative bacilli (GNB) from April 2006 to March 2008. Group 
2 carbapenems were restricted for use against GNB infections susceptible only to carbapenems and sus-
pected GNB infections in unstable patients. Cumulative susceptibility tests were done for nosocomial 
pathogens before and after restriction using Clinical and Laboratory Standards Institute (CLSI) guide-
lines. Vitek System or conventional identifi cation methods were performed and susceptibility testing done 
by disk diffusion according to CLSI. Antibiotic consumption (t-test) and susceptibilities (McNemar’s test) 
were determined. Results: The defi ned daily doses (DDD) of group 2 carbapenems declined from 61.1 to 
48.7 DDD/1,000 patient-days two years after ertapenem introduction (p = 0.027). Mean ertapenem con-
sumption after restriction was 31.5 DDD/1,000 patient-days. Following ertapenem introduction no sig-
nifi cant susceptibility changes were noticed among Gram-positive cocci. The most prevalent GNB were 
P. aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. There was no change in P. aeruginosa suscep-
tibility to carbapenems. Signifi cantly improved P. aeruginosa and K. pneumoniae ciproﬂ oxacin suscepti-
bilities were observed, perhaps due to decreased group 2 carbapenem use. K. pneumoniae susceptibility 
to trimethoprim-sulfamethoxazole improved. Conclusion: Preferential use of ertapenem resulted in re-
duced group 2 carbapenem use, with a positive impact on P. aeruginosa and K. pneumoniae susceptibility. 
Keywords: carbapenems; drug resistance; bacterial ecology.
[Braz J Infect Dis 2011;15(1):1-5]©Elsevier Editora Ltda.
INTRODUCTION
Susceptibility to the group 2 carbapenems, imi-
penem and meropenem, remains high even after 
decades of use.5 The more recently introduced 
group 1 carbapenem ertapenem has a differ-
ent spectrum of activity, with minimal activ-
ity against Pseudomonas aeruginosa; ertapenem 
has been described as a Pseudomonas-sparing 
carbapenem.2,12,16 The premise that ertapen-
em has minimal activity against P. aeruginosa 
and is thus less likely to select for resistance 
has been substantiated in vitro and in clinical 
settings.4,6,10,11 Still, the question of the long-term 
impact of ertapenem on hospital ecology lingers 
as overall concerns about antibiotic resistance 
become more pervasive.
Ertapenem is appropriate for the treatment 
of extended spectrum beta-lactamase (ESBL)-
producing Enterobacteriaceae, and thus provides 
a good weaponry to combat an increasingly im-
portant problem, particularly in an era when 
few new antibiotics are being introduced. The 
widespread use of ertapenem is likely to depend 
on long-term clinical evidence of the effect of 
ertapenem on the susceptibility of Gram-nega-
tive bacteria to the spectrum of antibiotics used.
ESBL-producing Enterobacteriaceae are a 
growing problem in Brazil as they are elsewhere; 
this problem can result in increased, and not al-
ways appropriate, carbapenem use.10,15 Antibiotic 
consumption and the prevalence of antibiotic re-
sistance are linked, giving institutional antibiotic 
use policies an important role in reducing the se-
lective pressure for resistance.9,15 The goal of this 
study was to evaluate the long-term impact of a 
carbapenem stewardship program on the hospi-
tal ecology at our facility, where ertapenem use 
was mandated for appropriate infections while 
group 2 carbapenems were restricted.
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2MATERIALS AND METHODS
Study design
This single-center study was conducted at the Institute of 
Orthopedics and Traumatology of Hospital das Clínicas, 
School of Medicine, Universidade de São Paulo, a 200-bed 
tertiary care facility that treats orthopedic and trauma pa-
tients. A mandatory antibiotic restriction policy was put 
in place in March 2006. Ertapenem use was mandated for 
infections caused by ESBL-producing Enterobacteriaceae 
for patients who did not have co-infection with non-fer-
menting Gram-negative bacilli. Before the restriction, group 
2 carbapenems were used to treat infections caused by ES-
BL-producing Enterobacteriaceae and infections caused by 
non-fermenting Gram-negative bacilli that were shown to 
be susceptible only to carbapenems. Following the restric-
tion group 2 carbapenems were used only to treat infections 
caused by non-fermenting Gram-negative bacilli infections 
sensitive to carbapenems alone and to treat suspected Gram-
negative infections in hemodynamically unstable patients 
who did not respond to other agents. Meropenem was not 
used from March 2005 to March 2006, but was used in the 
other periods of time included in the present study.
Antimicrobial susceptibility tests were obtained for no-
socomial pathogens (e.g. Enterobacteriaceae, Acinetobacter 
spp., and P. aeruginosa) isolated as the cause of nosocomial 
infection, according to the defi nitions of the Centers for 
Disease Control and Prevention (CDC)3, for the 24 months 
before and the 24 months after ertapenem introduction in 
March 2006. Cumulative susceptibility tests were done for 
nosocomial pathogens before and after restriction using 
Clinical and Laboratory Standards Institute (CLSI) guide-
lines. Strains were identifi ed by Vitek 1 automated microbial 
identifi cation system. Enterobacteriaceae susceptibility tests 
were done using the GNS 655 card. Susceptibility to ertap-
enem was extrapolated from imipenem results, according to 
CLSI standards during the time this study was performed.13 
Susceptibility tests for non-fermenting bacteria were done 
by disk diffusion (CLSI M100-S16).Quality control followed 
the CLSI standards.
Data analysis
Antimicrobial susceptibility was measured as the proportion 
of susceptible isolates of each bacterium to the antimicrobi-
als tested. The statistical signifi cance susceptibility changes 
before and after the restriction was assessed using the Chi-
square test. Consumption of antimicrobial agents was 
measured as the number of defined daily doses (DDD) 
per 1,000 patient-days, calculated for each month be-
fore and after the restriction. The mean consumptions 
before and after the restriction were compared using t-tests 
on the log-transformed data. Generally concordant results 
were obtained using a t-test performed on the raw data. 
Stability of the number of patient-days, length of stay, the 
numbers of deaths, and the hospital mortality index were 
also evaluated using these methods. The Durbin-Watson 
test for autocorrelation was used to rule out the possibility 
of false positive results that might have been caused by auto-
correlation of the monthly data series. The p-values < 0.05 
were considered to be indicative of statistically signifi cant 
comparisons; these tests are observational, however, and 
should be interpreted in conjunction with clinical judgment.
RESULTS
The average defi ned daily doses (DDD) of group 2 carbap-
enems declined from 61.1 to 48.7 DDD/1,000 patient-days 
two years after ertapenem was mandated for treatment of 
susceptible infections caused by ESBL-producing Entero-
bacteriaceae (p = 0.027).This represented a 20.2% decrease 
in group 2 carbapenem average consumption from the 
24 months before the restriction to the 24 months after. 
Imipenem use decreased by 58.7%; meropenem was used 
only sporadically during the 24 months prior to the re-
striction thus the mean change in use was not assessed. 
The mean ertapenem consumption after the restriction 
was 31.5 DDD/1,000 patient-days.
No signifi cant antibiotic susceptibility changes were 
noticed among Gram-positive cocci following ertapenem 
introduction (Table 1). The most prevalent Gram-negative 
bacteria that caused infection were P. aeruginosa, Klebsiella 
pneumoniae, and Acinetobacter spp. There were no changes 
in P. aeruginosa susceptibility to imipenem before and af-
ter the restriction (55% and 57%, respectively). Improved 
P. aeruginosa (from 28% to 57%) and K. pneumoniae (from 
12% to 40%) ciproﬂ oxacin susceptibilities were observed 
before and after the restriction, although ciproﬂ oxacin use 
did not change signifi cantly (before: 41.7 ± 17.4 DDD, af-
ter: 70.7 ± 34.5 DDD; p = 0.057). Although K. pneumoniae 
susceptibility to trimethoprim-sulfamethoxazole improved 
from 24% before the restriction to 60%, trimethoprim-
sulfamethoxazole consumption was low before and after the 
restriction (0.92 ± 2.27 DDD before to 2.35 ± 2.97 DDD af-
ter, p = 0.001), so the increase may not be clinically relevant. 
Acinetobacter spp. susceptibility to carbapenems decreased, 
a trend also seen in the other departments within our hos-
pital complex that did not have an ertapenem policy use 
(F Rossi and J N Almeida Jr, unpublished data).
In the 24 months before ertapenem introduction, 45% 
of all P. aeruginosa isolates were imipenem resistant. In the 
24 months after restriction, 43% of isolates were resistant 
to imipenem, suggesting that ertapenem did not impact 
P. aeruginosa susceptibility to imipenem.
The mortality index slightly lower after the restriction 
was observed (mean ± SD 0.95 ± 0.39 before and 0.71 ± 0.45 
after the restriction, p = 0.035). There were no clinically rel-
evant changes in other outcomes. The median length of stay 
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Table 1. Antimicrobial susceptibilities for the most frequent agents related to nosocomial infections before and 
after ertapenem introduction
Pathogen/Antibiotic  Susceptibility (%) Susceptibility (%)
(no isolates collected before/ 2 years before 2 years after
after ertapenem policy) ertapenem use ertapenem use
S. aureus (100/76)
Cephalotin 30 32
Clindamycin 33 32
Methicillin 30 31
Trimethoprim-sulfamethoxazole 33 3
Vancomycin 100 100
A. baumanii (64/36)
Amikacin 15 12
Cefepime 6 11
Ceftazidime 78 8
Ceftriaxone 14 3
Ciprofloxacin 3 11
Imipenem 64 33
Trimethoprim-sulfamethoxazole 6 17
P. aeruginosa (51/42)
Amikacin 68 67
Cefepime 43 57
Ceftazidime 61 62
Ciprofloxacin 28 57
Imipenem 55 57
Coagulase-negative Staphylococci (49/39)
Cephalotin 8 8
Clindamycin 20 20
Methicillin 8 8
Trimethoprim-sulfamethoxazole 43 8
Vancomycin 100 100
E. faecalis (39/28)
Ampicillin 92 46
Gentamicin 61 25
Penicillin 4 86
Vancomycin 73 79
K. pneumoniae (25/35)
Amikacin 76 97
Cefepime 16 17
Ceftazidime 20 11
Cefotaxime 8 11
Ceftriaxone 8 9
Ciprofloxacin 12 40
Imipenem 100 100
Trimethoprim-sulfamethoxazole 24 60
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4was 7.11 ± 0.74 days before and 6.89 ± 0.5 days after the re-
striction (p = 0.306); the number of deaths due to infection 
was 4.71 ± 2.05 before and 3.63 ± 2.41 after the restriction 
(p = 0.074). Overall, these data suggest that the severity of 
illness would have been similar during the two periods and 
that any observed decrease in Pseudomonas-resistant isolates 
would not be due to differences in the severity of illness.
DISCUSSION
Instituting ertapenem use for ESBL-producing Entero-
bacteriaceae infections in the absence of non-fermenting 
Gram-negative bacilli while restricting group 2 carbapen-
ems had a positive effect on the overall hospital ecology at 
our institution. In particular, increased ertapenem use had, 
in an indirect way, positive impact on the susceptibility of 
P. aeruginosa to imipenem, perhaps related to decreased use 
of group 2 carbapenems. There was no evidence of carbap-
enem resistance development associated with ertapenem 
use. Ertapenem use heralded improvements in the suscepti-
bilities of P. aeruginosa and K. pneumoniae to ciproﬂ oxacin, 
again perhaps due to a decrease in group 2 carbapenem 
use. An improvement in K. pneumoniae susceptibility to 
trimethoprim-sulfamethoxazole was noticed. We observed a 
decrease in Acinetobacter susceptibility to imipenem. In the 
broader context of data collected from across our institution 
and analyzed by the Microbiology Laboratory of Hospital 
das Clinicas (F Rossi and J N Almeida Jr, unpublished data), 
a downward trend was also observed for susceptibility of 
Acinetobacter to group 2 carbapenems from 2005 to 2008 
despite there being no ertapenem use policy in place. This 
could suggest that the Acinetobacter susceptibility trends 
were independent of ertapenem use.
Signifi cant correlations between the consumption 
of specifi c antibiotics and resistance have been reported 
for Gram-negative bacteria including P. aeruginosa and 
Acinetobacter.8,9,13 The rate of consumption of specifi c anti-
biotics is also related to the prevalence of resistance among 
nosocomial pathogens.9 Examining correlations between 
consumption of specifi c antimicrobials and antibiotic resist-
ance can assist in putting effective antimicrobial use poli-
cies in place in hospitals. Imipenem resistance, for example, 
has been linked to the use of amikacin, ciproﬂ oxacin, and 
ceftazidime, but not to ertapenem.9,11 Implementation of in-
terventions such as the one we describe here can have a posi-
tive impact on antimicrobial resistance, because inappropri-
ate antibiotic use is a main driver of resistance.15 Goldstein 
et al. reported that adding ertapenem to the formulary in a 
344-bed community hospital was an effective antimicrobial 
management tool.7
Apisarnthanarak et al. demonstrated that conducting 
surveillance and implementing prescribing policies resulted 
in reductions in antibiotic consumption and resistance in a 
tertiary care hospital in a developing country.1 This is consist-
ent with our experience. Our research was part of an ongoing 
close monitoring of antimicrobial resistance patterns in our 
hospital following ertapenem introduction. The data report-
ed here were consistent with prior results detailing the impact 
of ertapenem on hospital ecology within our institution.10,11 
The policies for rational use of carbapenems should al-
ways be encouraged, since it has been observed a worldwide 
dissemination of multidrug-resistant Gram-negative bacilli, 
with few therapeutic options. Indiscriminate use of carbap-
enems is one reason for this problem. It is also necessary to 
remember the rapidly increasing prevalence of Enterobacte-
riaceae harboring carbapenemases. From 2000 to 2007, the 
proportion of carbapenem-resistant Klebsiella spp. involved 
in nosocomial infections in the United States grew from less 
than 1% to 8% of the total Klebsiella spp. isolates.17
Our study provides long-term clinical data indicating 
that ertapenem is associated with a minimal risk of resist-
ance, and that ertapenem use may improve overall hospital 
ecology by decreasing excess use of group 2 carbapenems. 
These results suggest that ertapenem may have an important 
place in the treatment of ESBL-producing Enterobacteriace-
ae infections in the absence of Pseudomonas, and that anti-
biotic use policies that promote stewardship may decrease 
antibiotic resistance. 
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